| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 13, 2014Data Demonstrate Strong Closure Rates in Patients with Chronic Venous Insufficiency, Varicose Veins
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 13, 2014-- Covidien plc (NYSE:COV) today announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the...
-
Nov 5, 2014Fourth-quarter net sales up 7%; Medical Devices sales up 8%
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 5, 2014-- Covidien plc (NYSE: COV) today announced financial results for the fourth quarter of fiscal 2014. Fourth-quarter net sales of $2.73 billion...
-
Nov 5, 2014EverFlex™ Self-Expanding Stent System Safe and Effective for the Treatment of Iliac Stenosis
LAS VEGAS--(BUSINESS WIRE)--Nov. 5, 2014-- Covidien plc (NYSE: COV) today announced nine-month results of the DURABILITY Iliac study and addition of the iliac indication for its EverFlex™ stent...
-
Nov 4, 2014The HawkOne™ System strengthens Covidien’s directional atherectomy platform with a versatile solution for the treatment of peripheral arterial disease
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 4, 2014-- Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The...
-
Nov 4, 2014Results suggest long-term benefits for peripheral artery disease patients treated with directional atherectomy followed by a drug-coated balloon
LAS VEGAS--(BUSINESS WIRE)--Nov. 4, 2014-- Covidien plc (NYSE: COV) today announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical...